×
About 28,428 results

ALLMedicine™ Hodgkin Lymphoma Center

Research & Reviews  7,940 results

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01695941

Jan 27th, 2023 - PRIMARY OBJECTIVES: I. To determine the recommended phase II dose of alisertib (MLN8237) and bortezomib when combined with rituximab in patients with relapsed/refractory mantle cell and B-cell low grade non-Hodgkin lymphoma. SECONDARY OBJECTIVES: ...

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
https://clinicaltrials.gov/ct2/show/NCT03904134

Jan 27th, 2023 - This is a multicenter, interventional and observational study to understand factors affecting the likelihood of transplantation in patients without a human leukocyte antigen (HLA) matched family donor and to compare outcomes associated with pursui...

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory c...
https://doi.org/10.3324/haematol.2022.282266
Haematologica Ding K, Liu H et. al.

Jan 27th, 2023 - Although classic Hodgkin lymphoma (cHL) is highly curable with current treatment paradigms, 10-25% of patients experience therapeutic failure. This prospective multicenter phase II study attempted to investigate the efficacy and safety of the comb...

Survivors of Pediatric HL May Face Accelerated Aging.
https://doi.org/10.1158/2159-8290.CD-NB2023-0007
Cancer Discovery;

Jan 27th, 2023 - A study of long-term survivors of pediatric Hodgkin lymphoma presented at the 2022 American Society of Hematology Annual Meeting and Exposition shows that they have an increased risk for cognitive impairment and early death when compared with indi...

Cheng PTM, Villa D, Tonseth RP, et al. Outcome of limited-stage nodular lymphocyte-pred...
https://doi.org/10.1182/bloodadvances.2022007162
Blood Advances;

Jan 27th, 2023 - Cheng PTM, Villa D, Tonseth RP, et al. Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. Blood Adv. 2021;5(18):3647-3655.|2023||

see more →

Guidelines  17 results

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, A...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723685
Journal of Clinical Oncology : Official Journal of the Am... Mulder RL, Hudson MM et. al.

Oct 21st, 2020 - As new evidence is available, the International Late Effects of Childhood Cancer Guideline Harmonization Group has updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer. We used ev...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow...
https://doi.org/10.1093/annonc/mdy080
Annals of Oncology : Official Journal of the European Soc... Eichenauer DA, Aleman BMP et. al.

Oct 1st, 2018 - Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2018|Eichenauer DA,Aleman BMP,André M,Federico M,Hutchings M,|diagnosis,epidemiology,therapy,standards,

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in ...
https://doi.org/10.6004/jnccn.2018.0066
Journal of the National Comprehensive Cancer Network : JN... Reid E, Suneja G et. al.

Aug 14th, 2018 - People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment ...

see more →

Drugs  70 results see all →

Clinicaltrials.gov  896 results

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
https://clinicaltrials.gov/ct2/show/NCT03904134

Jan 27th, 2023 - This is a multicenter, interventional and observational study to understand factors affecting the likelihood of transplantation in patients without a human leukocyte antigen (HLA) matched family donor and to compare outcomes associated with pursui...

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01695941

Jan 27th, 2023 - PRIMARY OBJECTIVES: I. To determine the recommended phase II dose of alisertib (MLN8237) and bortezomib when combined with rituximab in patients with relapsed/refractory mantle cell and B-cell low grade non-Hodgkin lymphoma. SECONDARY OBJECTIVES: ...

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hod...
https://clinicaltrials.gov/ct2/show/NCT05283720

Jan 27th, 2023 - B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplast...

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
https://clinicaltrials.gov/ct2/show/NCT05371054

Jan 27th, 2023 - Background: High unmet medical need for relapsed/refractory non-Hodgkin lymphoma (NHL) after exhausting chemotherapy and/or chemo-immunotherapy regimens Targeted therapies aimed at disrupting cell death pathway in hematologic malignancies are emer...

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-...
https://clinicaltrials.gov/ct2/show/NCT05315713

Jan 27th, 2023 - This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicul...

see more →

News  2,426 results

Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphoma
https://www.medpagetoday.com/hematologyoncology/lymphoma/102579

Jan 10th, 2023 - Brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) after autologous hematopoietic stem-cell transplantation (HSCT) resulted in improved outcomes in patients with high-risk relapsed or refractory classic Hodgkin lymphoma, many of...

Four-gene signature linked to increased PML risk
https://www.mdedge.com/neurology/article/260315/multiple-sclerosis/four-gene-signature-linked-increased-pml-risk
Neil Osterweil

Dec 21st, 2022 - Any of four variants of genes associated with immunity can significantly increase a carrier’s risk for developing progressive multifocal leukoencephalopathy (PML) after exposure to immunosuppressing drugs, a team of European and U. S.

Steep Price for Surviving Childhood Lymphoma: Epigenetic Aging
https://www.medscape.com/viewarticle/985496

Dec 13th, 2022 - NEW ORLEANS — Children with Hodgkin lymphoma can be cured with intensive chemotherapy, radiation, and other modalities, but a large majority of patients who survive into adulthood may pay a steep price years later in terms of accelerated aging and...

ASH 2022: New Clinical Data Challenge Long-held Assumptions
https://www.medscape.com/viewarticle/984997

Dec 5th, 2022 - NEW ORLEANS — In addition to news on the latest in clinical care and drug development, some eyebrow-raising findings that challenge long-held but untested assumptions are promised from the annual meeting of the American Society of Hematology. The ...

Year in Review: Non-Hodgkin Lymphoma
https://www.medpagetoday.com/hematologyoncology/lymphoma/102027

Dec 2nd, 2022 - Developments in non-Hodgkin lymphoma in 2022 were punctuated by new indications for chimeric antigen receptor (CAR) T-cell therapies, the FDA's crackdown on PI3K inhibitors, and a new warning about breast implant-related lymphomas. Indications Com...

see more →

Patient Education  22 results see all →